Optimizing Safety and Adherence in HER2-Targeted Therapy Through Nursing and AE Management

EP: 1.Evolving Horizons in HER2-Positive Breast Cancer Care

EP: 2.Key HER2+ Patient Populations Evaluated in the DESTINY-Breast Program

EP: 3.Integrating Emerging DESTINY-Breast Data Into HER2+ Treatment Strategies

EP: 4.Interpreting Key Data From KATHERINE, HER2CLIMB-05, and PATINA

EP: 5.Defining Success in Metastatic Breast Cancer Trial Design

EP: 6.Personalized Selection of HER2+ Breast Cancer Therapies

EP: 7.Navigating ADC Use and Sequencing in HER2+ Breast Cancer

EP: 8.Balancing Efficacy and Safety in HER2+ Breast Cancer Trials

EP: 9.Exploring Off-Label HER2-Targeted Therapy in Early Breast Cancer

Now Viewing

EP: 10.Optimizing Safety and Adherence in HER2-Targeted Therapy Through Nursing and AE Management

The nurse navigator plays a critical role in supporting patients on HER2-targeted therapies by promoting adherence, monitoring for adverse events, and providing education on symptom recognition and reporting. Managing toxicities, such as interstitial lung disease (ILD) associated with antibody-drug conjugates (ADCs), requires balancing potential risks with clinical benefit. Clinicians often implement proactive monitoring strategies and dose modifications to mitigate ILD while maintaining efficacy. Standardized protocols for ILD and other adverse events are increasingly recognized as essential, ensuring consistent care across institutions. Developing an adverse event management protocol involves a multidisciplinary team including nursing staff, oncologists, pharmacy, and informatics support through EMR order sets. Clear roles and communication pathways allow timely interventions, optimize patient safety, and support adherence, ultimately improving outcomes and the tolerability of HER2-targeted therapies acros